KRAS and lung carcinoma: Recently, the novel compound sotorasib has demonstrated activity, as it occupies the His95 groove near the cysteine pocket to maintain high levels of inactive KRAS.14 Initial results are encouraging in lung cancers that harbor KRAS G12C mutation.